BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Volante M, Rosas R, Allìa E, Granata R, Baragli A, Muccioli G, Papotti M. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol. 2008;286:219-229. [PMID: 18248880 DOI: 10.1016/j.mce.2007.12.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Pearce TR, Shroff K, Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv Mater 2012;24:3803-22, 3710. [PMID: 22674563 DOI: 10.1002/adma.201200832] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 13.6] [Reference Citation Analysis]
2 Storvall S, Leijon H, Ryhänen E, Louhimo J, Haglund C, Schalin-Jäntti C, Arola J. Somatostatin receptor expression in parathyroid neoplasms. Endocr Connect 2019;8:1213-23. [PMID: 31336364 DOI: 10.1530/EC-19-0260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Yan L, Xing Z, Guo Z, Fang Z, Jiao W, Guo X, Xu Z, Fang Z, Holmberg A, Nilsson S, Liu Z. Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy. PLoS One 2013;8:e55790. [PMID: 23409045 DOI: 10.1371/journal.pone.0055790] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
4 Fani M, Mansi R, Nicolas GP, Wild D. Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. Cancers (Basel) 2022;14:1172. [PMID: 35267479 DOI: 10.3390/cancers14051172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kaemmerer D, Specht E, Sänger J, Wirtz RM, Sayeg M, Schulz S, Lupp A. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab 2015;100:831-40. [PMID: 25494861 DOI: 10.1210/jc.2014-2699] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
6 Luque RM, Cordoba-Chacon J, Pozo-Salas AI, Porteiro B, de Lecea L, Nogueiras R, Gahete MD, Castaño JP. Obesity- and gender-dependent role of endogenous somatostatin and cortistatin in the regulation of endocrine and metabolic homeostasis in mice. Sci Rep 2016;6:37992. [PMID: 27901064 DOI: 10.1038/srep37992] [Reference Citation Analysis]
7 Sancak S, Hardt A, Singer J, Klöppel G, Eren FT, Güllüoglu BM, Sen LS, Sever Z, Akalin NS, Eszlinger M, Paschke R. Somatostatin Receptor 2 Expression Determined by Immunohistochemistry in Cold Thyroid Nodules Exceeds That of Hot Thyroid Nodules, Papillary Thyroid Carcinoma, and Graves' Disease. Thyroid 2010;20:505-11. [DOI: 10.1089/thy.2009.0203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
8 Martino MCD, Hofland LJ, Lamberts SW. Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications. Neuroendocrinology - Pathological Situations and Diseases. Elsevier; 2010. pp. 255-80. [DOI: 10.1016/s0079-6123(10)82011-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Luque RM, Cordoba-Chacon J, Pozo-Salas AI, Porteiro B, de Lecea L, Nogueiras R, Gahete MD, Castaño JP. Obesity- and gender-dependent role of endogenous somatostatin and cortistatin in the regulation of endocrine and metabolic homeostasis in mice. Sci Rep 2016;6:37992. [PMID: 27901064 DOI: 10.1038/srep37992] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Zhang J, Jin W, Wang X, Wang J, Zhang X, Zhang Q. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm. 2010;7:1159-1168. [PMID: 20524673 DOI: 10.1021/mp1000235] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 6.6] [Reference Citation Analysis]
11 Rajora AK, Ravishankar D, Zhang H, Rosenholm JM. Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy. Pharmaceutics 2020;12:592. [DOI: 10.3390/pharmaceutics12060592] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
12 Worm DJ, Els‐heindl S, Beck‐sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Peptide Science 2020;112. [DOI: 10.1002/pep2.24171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
13 Zheng N, Dai W, Du W, Zhang H, Lei L, Zhang H, Wang X, Wang J, Zhang X, Gao J, Zhang Q. A Novel Lanreotide-Encoded Micelle System Targets Paclitaxel to the Tumors with Overexpression of Somatostatin Receptors. Mol Pharmaceutics 2012;9:1175-88. [DOI: 10.1021/mp200464x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
14 Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int 2015;2015:917968. [PMID: 25879040 DOI: 10.1155/2015/917968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rol Á, Todorovski T, Martin-Malpartida P, Escolà A, Gonzalez-Rey E, Aragón E, Verdaguer X, Vallès-Miret M, Farrera-Sinfreu J, Puig E, Fernández-Carneado J, Ponsati B, Delgado M, Riera A, Macias MJ. Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease. Nat Commun 2021;12:1869. [PMID: 33767180 DOI: 10.1038/s41467-021-22076-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020;8:571. [PMID: 32733853 DOI: 10.3389/fchem.2020.00571] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
17 Wang T, Wu Y, Kuan SL, Dumele O, Lamla M, Ng DY, Arzt M, Thomas J, Mueller JO, Barner-Kowollik C, Weil T. A disulfide intercalator toolbox for the site-directed modification of polypeptides. Chemistry 2015;21:228-38. [PMID: 25359430 DOI: 10.1002/chem.201403965] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
18 Marchiani S, Tamburrino L, Nesi G, Paglierani M, Gelmini S, Orlando C, Maggi M, Forti G, Baldi E. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation. Int J Androl 2010;33:784-93. [PMID: 20088946 DOI: 10.1111/j.1365-2605.2009.01030.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
19 Wu H, Zeng M, Cho EY, Jiang W, Sha O. The Origin, Expression, Function and Future Research Focus of a G Protein-coupled Receptor, Mas-related Gene X2 (MrgX2). Progress in Histochemistry and Cytochemistry 2015;50:11-7. [DOI: 10.1016/j.proghi.2015.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
20 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Reference Citation Analysis]
21 Kuan SL, Wang T, Raabe M, Liu W, Lamla M, Weil T. Programming Bioactive Architectures with Cyclic Peptide Amphiphiles. Chempluschem 2015;80:1347-53. [PMID: 31973290 DOI: 10.1002/cplu.201500218] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Feelders RA, Hofland LJ, Kwekkeboom DJ, Lamberts S, de Herder WW. Neuroendocrine Tumors. Handbook of Neuroendocrinology. Elsevier; 2012. pp. 761-78. [DOI: 10.1016/b978-0-12-375097-6.10035-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Essand M. Virotherapy of neuroendocrine tumors. Neuroendocrinology 2013;97:26-34. [PMID: 22378183 DOI: 10.1159/000336084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
24 Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 2011;18:R233-51. [PMID: 22135243 DOI: 10.1530/ERC-10-0334] [Cited by in Crossref: 57] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
25 Zarogoulidis K, Eleftheriadou E, Kontakiotis T, Gerasimou G, Zarogoulidis P, Sapardanis I, Galaktidou G, Sakkas L, Gotzamani-Psarrakou A, Karatzas N. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung Cancer 2012;76:84-8. [PMID: 22018594 DOI: 10.1016/j.lungcan.2011.09.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
26 Moncayo R. Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis. EJNMMI Res 2011;1:9. [PMID: 22214590 DOI: 10.1186/2191-219X-1-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Liu W, Boldt F, Tokura Y, Wang T, Agrawalla BK, Wu Y, Weil T. Encoding function into polypeptide-oligonucleotide precision biopolymers. Chem Commun (Camb) 2018;54:11797-800. [PMID: 30280162 DOI: 10.1039/c8cc04725a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Yue M, Xia Y, Shi C, Guan C, Li Y, Liu R, Wei Z, Dai Y. Berberine ameliorates collagen-induced arthritis in rats by suppressing Th17 cell responses via inducing cortistatin in the gut. FEBS J 2017;284:2786-801. [PMID: 28636167 DOI: 10.1111/febs.14147] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
29 Specht E, Kaemmerer D, Sänger J, Wirtz RM, Schulz S, Lupp A. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology 2015;67:368-77. [PMID: 25641082 DOI: 10.1111/his.12662] [Cited by in Crossref: 57] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
30 Annunziata M, Luque RM, Durán-Prado M, Baragli A, Grande C, Volante M, Gahete MD, Deltetto F, Camanni M, Ghigo E, Castaño JP, Granata R. Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Hum Reprod 2012;27:2117-29. [PMID: 22588000 DOI: 10.1093/humrep/des144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
31 Chougnet CN, Leboulleux S, Caramella C, Lumbroso J, Borget I, Déandreis D, Duvillard P, Elias D, de Baere T, Vélayoudom-céphise F, Guigay J, Ducreux M, Schlumberger M, Baudin E. Frequency and characterization of gastro–entero–pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. Endocrine-Related Cancer 2013;20:229-39. [DOI: 10.1530/erc-12-0169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011;96:665-71. [PMID: 21193541 DOI: 10.1210/jc.2010-2022] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
33 Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, Schulz S, Gracia-Navarro F, Malagón MM, Castaño JP. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 2009;94:2634-43. [PMID: 19401364 DOI: 10.1210/jc.2008-2564] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 8.2] [Reference Citation Analysis]
34 Ferro P, Krotov G, Zvereva I, Rodchenkov G, Segura J. Structure-activity relationship for peptídic growth hormone secretagogues. Drug Test Anal 2017;9:87-95. [PMID: 26811125 DOI: 10.1002/dta.1947] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
35 Chen W, Fu Y, Yin X, Liu Y. Circulating levels of cortistatin are correlated with metabolic parameters in patients with newly diagnosed type 2 diabetes mellitus. Peptides 2017;94:86-90. [PMID: 28526556 DOI: 10.1016/j.peptides.2017.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
36 Luque RM, Villa-Osaba A, L-López F, Pozo-Salas AI, Sánchez-Sánchez R, Ortega-Salas R, de Lecea L, Álvarez-Benito M, López-Miranda J, Gahete MD, Castaño JP. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res 2016;18:29. [PMID: 26956474 DOI: 10.1186/s13058-016-0689-1] [Reference Citation Analysis]
37 Luque RM, Villa-Osaba A, L-López F, Pozo-Salas AI, Sánchez-Sánchez R, Ortega-Salas R, de Lecea L, Álvarez-Benito M, López-Miranda J, Gahete MD, Castaño JP. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res 2016;18:29. [PMID: 26956474 DOI: 10.1186/s13058-016-0689-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
38 Moaeen-ud-Din M, Malik N, Guo YL, Ali A, Babar ME. Cortistatin vaccination--a solution to growth hormone deficiency. Med Hypotheses 2009;73:1053-4. [PMID: 19560289 DOI: 10.1016/j.mehy.2009.05.020] [Reference Citation Analysis]
39 Böhme D, Beck-Sickinger AG. Drug delivery and release systems for targeted tumor therapy. J Pept Sci 2015;21:186-200. [PMID: 25703117 DOI: 10.1002/psc.2753] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 10.0] [Reference Citation Analysis]
40 Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401 [PMID: 27096034 DOI: 10.4251/wjgo.v8.i4.389] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
41 Dai W, Jin W, Zhang J, Wang X, Wang J, Zhang X, Wan Y, Zhang Q. Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes. Pharm Res 2012;29:2902-11. [DOI: 10.1007/s11095-012-0797-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
42 Nik ME, Momtazi‐borojeni AA, Zamani P, Navashenaq JG, Iranshahi M, Jaafari MR, Malaekeh‐nikouei B. Targeted‐nanoliposomal combretastatin A4 (CA‐4) as an efficient antivascular candidate in the metastatic cancer treatment. J Cell Physiol 2019;234:14721-33. [DOI: 10.1002/jcp.28230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
43 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
44 Zheng N, Dai W, Zhang H, Wang X, Wang J, Zhang X, Wang K, Li J, Zhang Q. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors. J Drug Target 2015;23:67-78. [PMID: 25366085 DOI: 10.3109/1061186X.2014.954118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]